Price broke below the trendline, could be a fakeout! Fundamentals are still strong for equity market, not worrying about crash, but think it could be a good pullback to add some positions here !
"Assertio is a pharmaceutical company that sells prescription products in 3 areas: neurology, hospital, and pain and inflammation. The company is currently undergoing major restructuring and has recently merged with Zyla Life Sciences. They have 7 FDA approved products in the marketplace. Assertio currently has a market cap of only $150 million and has raised $50...
#ENLV is in the news last week with regards to Covid-19 treatment. I would be looking at the 18.46 area for a retest, and possible entry if we find support. 100% measured move would take the breakout to 23.81 and ultimately that would be my first target. Id consider this trade still healthy above 15.49 and ultimately any lower than 14.54 i would stop out of a...
ETNB long, longer-term play 89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA. Pre-revenue, early stage company.
BIO BUY CALL 600 jun18 6000$ 218days cmp: 599 pro: 1.Health care sector is a hot sector during covid 2. weekly demand and bouncing in daily as confirmation 3.Aggreessive stock 4.Stock making constantly HH HL in weekly demand
BIO-key, Provider of Multi-Factor Identity and Access Management Solutions, Hosts Q2 Investor Call Friday, Aug 14 at 10am ET. Innovative Credit Card Processor Clearent, LLC Switches to BIO-key’s PortalGuard Identity and Access Management Solution to Secure Customer Access and Deliver Secure Reset Capabilities. Source: yahoo finance The analysts are targeting a...
All, See my previous post on my baby aka favorite stock. My entry was $2.28 on this. There pipeline was epic, FDA approvals and no price movement. Now it just hit every scanner and radar out there. I would not buy in now of course, but over time it will come back and retest the last high it left from. It may happen quickly but I would put my alert around 50% of...
First off, THIS IS A RISKY BET. I got in at .082 yes... less than a dime. There was news they are doing antibody COVID testing. This got 40M volume x8 its relative volume. Like I said extremely risky. Watch it today and see what happens. Personally I just bought 3000 shares because I don't care if I lose $250 just to see. finance.yahoo.com
Read the news on last two AGEN articles.. approved for FDA and beat the EPS... This is a monthly chart and i can at LEAST see x2 profits ahead.
Do Not Trade This! I'd personally wait for a retest around $6.90 before making my move. Might buy a few shares for fun tomorrow and see how it rolls. For premium crypto & option signals, direct message me or @Kyer DotcomJack | Easy Loot
$BIO just broke the pivot but RSI is still below the trend. It may stall on nextweek.
Biotech situated for nice influx of capital worldwide.
Buying opportunity with potential downside of 20% and potential upside of 80% plus
Will have a serious drop soon. But it's all the set up for the bullish BAT pattern guys.
Another pharma company - with amazing correct Elliot 5 waves which you can try to ride. 1. Buy 131.32 2. Take profit: 213 3. SL: 115.90 RISK/REWARD: 5.38, potential profit 62.39%
NASDAQ:MBIO Mustang Bio Inc Stock - NASDAQ (USA) Tested main volume after that we go up. Profit:Risk = 3:1 --- Buy = $5.97 Take Profit = $8.50 Stop Loss = $5.04 ------ Take Profit = +42.38% Stop Loss = -15.58%
Very undervalued stock. 52 Week High was $46.00 52 Week Low was $3.22 Revenue for the 4th quarter of 2018 was $35.5 million, an 739% increase year over year. Total revenue for the year is $96.4 million. Could do 2x-3x from this level. Key data presentations at ECCMID 2019 include: Integrated Symposium Presentations •“Update on acute bacterial skin and skin...